Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Keros Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Employee Stock Option (right to buy) | 40K | Feb 13, 2024 | Direct | ||
Keros Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 0 | $45.29 | Nov 4, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KROS | Keros Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | CHIEF FINANCIAL OFFICER |
KROS | Keros Therapeutics, Inc. | Nov 4, 2023 | 3 | -$1.17M | 4 | Jan 8, 2024 | Chief Financial Officer |
KROS | Keros Therapeutics, Inc. | Jun 8, 2023 | 9 | -$1.22M | 4 | Jun 12, 2023 | Chief Financial Officer |
KROS | Keros Therapeutics, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 17, 2023 | Chief Financial Officer |
KROS | Keros Therapeutics, Inc. | Jan 21, 2022 | 1 | $0 | 4 | Jan 25, 2022 | Chief Financial Officer |